Royalty Report: Drugs, Therapeutic, Pharmaceuticals – Collection: 279331

$100.00

Curated Royalty Rate Report
Created On: 2020-07-15, Record Count: 4

Description

This collection of transactions and supporting information was developed using our AI algorithm to curate similar royalty reports into a cohesive collection to support your licensing, transfer pricing or other transaction scenarios where documented royalty rates and/or deal terms are important.
Created On: 2020-07-15
Record Count: 4

Primary Industries

  • Drugs
  • Therapeutic
  • Pharmaceuticals

IPSCIO Report Record List

Below you will find the records curated into this collection.  This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs.  The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms.  For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report

IPSCIO Record ID: 279331

License Grant
The Koran Licensor grants to Licensee the license to use, import, package, sell, and offer for sale Products within the Field in the Territory.

The parties agreed to amend the agreement to include but not limited to Co-Promotion, Supply price for the API product, milestone and royalty payments.  Except as is expressly provided herein the License shall remain in full force and effect.

License Property
Product means any compound containing Gemifloxacin as an active ingredient, including API and Final Product.

API means Active Pharmaceutical Ingredient.

Gemifloxacin is a novel fluoroquinolone antibiotic.

Field of Use
Gemifloxacin is used to treat a variety of bacterial infections.  Gemifloxacin is used to treat different types of bacterial infections in the lungs.

The Licensee is marketing FACTIVE(R) (gemifloxacin mesylate) tablets, approved by the FDA for the treatment of acute bacterial exacerbations of chronic bronchitis and community-acquired pneumonia of mild to moderate severity.

IPSCIO Record ID: 4384

License Grant
The Canadian Licensee acquired the North American product rights for Factive® (Gemifloxacin Mesylate) tablets from the Licensor.
License Property
Factive® is an FDA-approved quinolone with 5-day oral dosing indicated for the treatment of both acute bacterial exacerbation of chronic bronchitis and mild to moderate community-acquired pneumonia.
Field of Use
The Licensee acquired the License to the FACTIVE® trademark and patent, inventory on hand, and certain related intellectual property and other information and materials required to continue marketing the brand in the North American market.

The Licensee has also entered into a sales and promotion Agreement for Factive® with Vansen Pharma Inc. to market the product in the United States.

IPSCIO Record ID: 279330

License Grant
The Korean Licensor grants to Licensee the sole and exclusive license to use, import, package, sell, and offer for sale Products within the Field in the Territory, and the exclusive right to use the Trademarks in the Territory in conjunction with the use or sale of the Products.  Licensor agrees to supply to Licensee Final Product or Active Pharmaceutical Ingredient (“API”).
License Property
Product means any compound containing Gemifloxacin as an active ingredient, including API and Final Product.

API means Active Pharmaceutical Ingredient.

Field of Use
Gemifloxacin is used to treat a variety of bacterial infections. This medication belongs to a class of drugs known as quinolone antibiotics.  Gemifloxacin is used to treat different types of bacterial infections in the lungs.

IPSCIO Record ID: 263068

License Grant
Licensor granted Japanese Licensee the right to manufacture and procure such API and clinical supply, and forfeited rights to all future milestone payments related to Licensee’s development of solithromycin in Japan.  Under the terms of this Amended Agreement, Licensor is legally relieved of all obligations related to the supply of API or clinical supply to Licensee.
License Property
Solithromycin is an active pharmaceutical ingredient ('API') contained in our products and product candidates, as well as the preparation of finished products and their packaging for human therapeutic uses, other than for ophthalmic indications or any condition, disease or affliction of the ophthalmic tissues.

The Licensor is a commercial-stage pharmaceutical company focused on developing and commercializing differentiated anti-infectives for the hospital and select non-hospital, or community, settings that address the need for effective treatments for infections due to resistant gram-negative and gram-positive bacteria.  They currently market four antibiotics to treat a variety of infections caused by these resistant bacteria.

Solithromycin has been successfully evaluated in two Phase 3 clinical trials for community acquired bacterial pneumonia (CABP) and applications for approval for both intravenous and oral capsule formulations have been accepted for review by the FDA and the EMA.  Solithromycin is also in a Phase 3 clinical trial for uncomplicated urogenital urethritis caused by Neisseria gonorrhoeae or chlamydia.

Field of Use
Licensee owns exclusive rights to develop and commercialize solithromycin in Japan for respiratory tract infections and other indications in adults and pediatric patients.
Disclaimer: The information gathered from RoyaltySource® database was sourced from the U.S. Securities and Exchange Commission EDGAR Filings and other public records. While we believe the sources to be reliable, this does not guarantee the accuracy or completeness of the information provided. Further, the information is supplied as general guidance and is not intended to represent or be a substitute for a detailed analysis or professional judgment. This information is for private use only and may not be resold or reproduced without permission.